Starpharma Holdings Limited · ASX:SPL
Starpharma — Shareholder Meeting (November 2002)
14 slides from Starpharma's shareholder meeting presentation, Nov 27, 2002
Slide 1: The Dendrimer Businesses
ae si starp arma The Dendrimer Businesses ~] DENDRITIC NANOTECHNOLOGIES LIMITED
Slide 2: Dendrimers
Dendrimers Dendrimers are a basic building block of nanotechnology. Nanotechnology is the most exciting new technology of the 21st century. Nanotechnology has the potential to transform industries by producing a whole range of new products.
Slide 3: Starpharma's Investment in DNT
Starpharma’s Investment in DNT DNT, with its focus on dendrimers, is directly relevant to Starpharma’s core business: Provides access to additional dendrimer IP in pharmaceuticals, eg. drug delivery; Provides exposure to broader opportunities through dendrimer applications in other industries; Assis
Slide 4: DNT Recent Developments
DNT Recent Developments Appointment of an experienced business-focused CEO – Dr Charles Burke; US$3.5 Million grant from the US Department of Defense; Permission from the PDF Board to convert DNT into a US entity; Scientific developments, ie. lower cost synthesis methods for dendritic structures; Ma
Slide 5: Senator Carl Levin testimonial
“… I've seen a lot of presentations and lot of cases that are made for various technologies. This is one of the most impressive I've ever seen." Senator Carl Levin, Chairman US Senate Armed Services Committee The Senate Armed Services Committee controls a budget in excess of US$300 Billion p.a.
Slide 6: Central Michigan University
Central Michigan University ¾ Funding ¾ Intellectual Support ¾ Lab and Office Space ¾ Library – Journal Access ¾ IT, Telephone, Video Conferencing, Web Development ¾ Safety, OSHA, etc.
Slide 7: DNT's Opportunities
DNT’s Opportunities Nano - catalysts Nano - reagents Nano - optics Nano - electronics Military Nano - sensors Pharmaceutical Thin Films
Slide 8: DNT Business
DNT Business The “Dendrimer Store” • Sales of Dendritic Nano-Reagents for R&D Joint Development of New Nano - Products • Nano - Pharmaceutical • Biotech • Electronics New DNT Exclusive Products • Functional Nano - Films • Nano – sensors • Energy Transduction & Amplification
Slide 9: Vaginal Microbicide
Vaginal Microbicide Technology • Prevent transmission of STDs (including HIV) Status & Results • December 2002: Proposed filing of US FDA Investigational New Drug Application • Early 2003: Commence Phase I human safety clinical trials in Adelaide Opportunity • In yr 2002, 5m people worldwide were ne
Slide 10: Stage of Licensing
Stage of Licensing Out-license at Phase I/II • Significant in-house $ investment in development (e.g. Microbicide) • Royalty: 7-10% of sales • Milestone payments: $20m Out-license at Early Pre-Clinical: • Chemistry & biology plus Decrease in Increase in Value In-vivo result – proof of Development pr
Slide 11: Out-license at Early Stage v. Phase I/II
Out-license at Out-license at Early Stage v. Phase I/II ‘Technology’ Focus: ‘Product’ Focus: • HSV-1, Cancer, Toxins, Prions, • Microbicide West Nile Virus, Dengue, • Topical Herpes Therapeutic Malaria • Multiple Acting Anti-viral • Drug Delivery Respiratory • ‘Dendrimer Toolbox’ • Angiogenesis Inhi
Slide 12: Starpharma Finances
Starpharma Finances Low underlying operational expenditure of approximately $4 Million per annum. Non Recurring Costs: Fitting out of new premises – to provide state-of-the-art chemistry labs and corporate headquarters; Establishment of a new company with operations in the US (DNT); Funding the deve
Slide 13: Capturing Shareholder Value
Capturing Shareholder Value Licensing income Starpharma’s shareholding in DNT Strategic technology buyout Short term cash opportunities Products and services
Slide 14: The Year Ahead
The Year Ahead Successful US fundraising by DNT Achievement of regulatory milestones Strategic deals with other companies Licensing deals with other companies
Starpharma Holdings — Shareholder Meeting (November 2002) on 6ix